

February 4th, 2025

To whom it may concern:

## The Prospects for the development of the regenerative medicine cell product “AE101” in China

We would like to inform you of the development of the regenerative medicine cell product “AE101” (indication: bullous keratopathy) in the Chinese region (mainland China, Hong Kong, Macau, and Taiwan) and South Korea as follows:

### 1. Development status

Japan: Clinical trials are ongoing as planned; China: Clinical trials are scheduled to begin in 2025 by Arctic Vision

### 2. Prospects

We will steadily proceed with clinical trials in Japan and support the progress of development by Arctic Vision in China. We will also strive to provide new treatment options for patients suffering from bullous keratopathy in order to commercialize the product in both markets as soon as possible.

End

### **About Arctic Vision**

Arctic Vision is a China-based clinical stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The company’s vision is to address ophthalmology’s unmet needs through innovative therapies in China, Asia and globally. Arctic Vision was established by leading life science investors and is led by an elite team of experienced ophthalmic industry experts with substantial and compelling China and global experiences in both R&D and the commercialization of eye care products.

For more information, please visit <https://www.arcticvision.com>.

### **About AE101**

AE101 is a cultured human corneal endothelial cell frozen preparation obtained by amplifying and culturing human corneal endothelial cells in vitro and suspending them in a cryopreservation solution containing a Rho-kinase inhibitor. AE101 is injected into the anterior chamber of the eye to regenerate corneal endothelium.

### Explanation of terms

#### (Note 1) Bullous keratopathy

Bullous keratopathy occurs when corneal endothelial cell damage results in a swollen and cloudy cornea, leading to greatly weakened eyesight. It is associated with loss of corneal endothelial cells due to Fuchs’ endothelial corneal dystrophy (FECD) or surgery for cataracts or glaucoma. The recommended treatment is corneal keratoplasty.